A first approach to identifying cardiotoxic effects of breast cancer chemotherapeutic treatment in Kazakhstan
As known, the clinical efficacy of chemotherapy is limited by the cardiotoxicity of drugs used.<br /> <b>The study aimed </b>to clarify cardiotoxic complications of chemotherapy from the Aktobe Medical Center database for 2018-2019.<b> &...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
National Scientific Medical Center
2022-02-01
|
| Series: | Ķazaķstannyṇ Klinikalyķ Medicinasy |
| Subjects: | |
| Online Access: | https://www.clinmedkaz.org/download/a-first-approach-to-identifying-cardiotoxic-effects-of-breast-cancer-chemotherapeutic-treatment-in-11412.pdf |
| _version_ | 1830407602467504128 |
|---|---|
| author | Zhenisgul Tlegenova Saule Balmagambetova Bekbolat Zholdin Gulnara Kurmanalina Iliada Talipova Arip Koyshybaev Ainel Urazova Dinara Nurmanova Olzhas Urazayev Gulmira Sultanbekova Kulparshan Kubenova Mira Baspayeva |
| author_facet | Zhenisgul Tlegenova Saule Balmagambetova Bekbolat Zholdin Gulnara Kurmanalina Iliada Talipova Arip Koyshybaev Ainel Urazova Dinara Nurmanova Olzhas Urazayev Gulmira Sultanbekova Kulparshan Kubenova Mira Baspayeva |
| author_sort | Zhenisgul Tlegenova |
| collection | DOAJ |
| description | As known, the clinical efficacy of chemotherapy is limited by the cardiotoxicity of drugs used.<br />
<b>The study aimed </b>to clarify cardiotoxic complications of chemotherapy from the Aktobe Medical Center database for 2018-2019.<b> </b><br />
<b>Material and methods: </b>We performed a register study on essential parameters of the oncological process, drugs used, duration of chemotherapy, types of complications, and outcomes, including survival.<br />
<b>Results:</b> We found a total of 305 breast cancer cases. Chemotherapy was completed without complications in 65.9% of patients; treatment was interrupted due to complications - 10.5%; 6.2% of cardiovascular complications were identified. The two groups of patients, EchoCG + and EchoCG -, showed significant difference in the number of detected CV complications (p<.001) but no difference in the survival rate (p .814). The survival rate in patients with documented CV complications was 28.1 months vs. 34.3 months in the group without ones (p.005). The survival rate in those who completed the treatment without complications, was 34.9 months vs. 17.6 in individuals whose treatment was interrupted due to complications (p<.001). We performed a detailed review of four cases of cardiotoxicity with fatal outcomes. <br />
<b>Conclusion:</b> The analysis indicates the absence of a systematic approach to recording crucial information regarding cardiotoxicity. There is a lack of concordance in the actions of cardiologists and oncologists in the management of BC patients. The presence of lethal outcomes of chemotherapy with an established cause of cardiac death indicates the need to revise the cancer register management from the standpoint of cardio-oncology. In general, there is a need to develop local protocols for screening and monitoring patients undergoing cardiotoxic chemotherapy and radiation therapy.<br />
|
| first_indexed | 2024-12-20T18:32:56Z |
| format | Article |
| id | doaj.art-b2b702d9f25d4420a84043a58930c036 |
| institution | Directory Open Access Journal |
| issn | 1812-2892 2313-1519 |
| language | English |
| last_indexed | 2024-12-20T18:32:56Z |
| publishDate | 2022-02-01 |
| publisher | National Scientific Medical Center |
| record_format | Article |
| series | Ķazaķstannyṇ Klinikalyķ Medicinasy |
| spelling | doaj.art-b2b702d9f25d4420a84043a58930c0362022-12-21T19:29:59ZengNational Scientific Medical CenterĶazaķstannyṇ Klinikalyķ Medicinasy1812-28922313-15192022-02-01191283510.23950/jcmk/11412A first approach to identifying cardiotoxic effects of breast cancer chemotherapeutic treatment in KazakhstanZhenisgul Tlegenova0Saule Balmagambetova1Bekbolat Zholdin2Gulnara Kurmanalina3Iliada Talipova4Arip Koyshybaev5Ainel Urazova6Dinara Nurmanova7Olzhas Urazayev8Gulmira Sultanbekova9Kulparshan Kubenova10Mira Baspayeva11Department of Internal Diseases-2, West Kazakhstan Marat Ospanov Medical University, Aktobe, KazakhstanDepartment of Oncology, West Kazakhstan Marat Ospanov Medical University, Aktobe, KazakhstanDepartment of Internal Diseases-2, West Kazakhstan Marat Ospanov Medical University, Aktobe, KazakhstanDepartment of Internal Diseases-2, West Kazakhstan Marat Ospanov Medical University, Aktobe, KazakhstanDepartment of Internal Diseases-2, West Kazakhstan Marat Ospanov Medical University, Aktobe, KazakhstanDepartment of Oncology, West Kazakhstan Marat Ospanov Medical University, Aktobe, KazakhstanDepartment of Oncology, West Kazakhstan Marat Ospanov Medical University, Aktobe, KazakhstanDepartment of Internal Diseases-2, West Kazakhstan Marat Ospanov Medical University, Aktobe, KazakhstanDepartment of Oncology, West Kazakhstan Marat Ospanov Medical University, Aktobe, KazakhstanDepartment of Internal Diseases-2, West Kazakhstan Marat Ospanov Medical University, Aktobe, KazakhstanClinical Lab, University's Medical Center, Aktobe, KazakhstanChemotherapy Department, University`s Medical Center, Aktobe, KazakhstanAs known, the clinical efficacy of chemotherapy is limited by the cardiotoxicity of drugs used.<br /> <b>The study aimed </b>to clarify cardiotoxic complications of chemotherapy from the Aktobe Medical Center database for 2018-2019.<b> </b><br /> <b>Material and methods: </b>We performed a register study on essential parameters of the oncological process, drugs used, duration of chemotherapy, types of complications, and outcomes, including survival.<br /> <b>Results:</b> We found a total of 305 breast cancer cases. Chemotherapy was completed without complications in 65.9% of patients; treatment was interrupted due to complications - 10.5%; 6.2% of cardiovascular complications were identified. The two groups of patients, EchoCG + and EchoCG -, showed significant difference in the number of detected CV complications (p<.001) but no difference in the survival rate (p .814). The survival rate in patients with documented CV complications was 28.1 months vs. 34.3 months in the group without ones (p.005). The survival rate in those who completed the treatment without complications, was 34.9 months vs. 17.6 in individuals whose treatment was interrupted due to complications (p<.001). We performed a detailed review of four cases of cardiotoxicity with fatal outcomes. <br /> <b>Conclusion:</b> The analysis indicates the absence of a systematic approach to recording crucial information regarding cardiotoxicity. There is a lack of concordance in the actions of cardiologists and oncologists in the management of BC patients. The presence of lethal outcomes of chemotherapy with an established cause of cardiac death indicates the need to revise the cancer register management from the standpoint of cardio-oncology. In general, there is a need to develop local protocols for screening and monitoring patients undergoing cardiotoxic chemotherapy and radiation therapy.<br /> https://www.clinmedkaz.org/download/a-first-approach-to-identifying-cardiotoxic-effects-of-breast-cancer-chemotherapeutic-treatment-in-11412.pdfbreast cancercancer registerchemotherapycardiovascular eventscardiotoxicity |
| spellingShingle | Zhenisgul Tlegenova Saule Balmagambetova Bekbolat Zholdin Gulnara Kurmanalina Iliada Talipova Arip Koyshybaev Ainel Urazova Dinara Nurmanova Olzhas Urazayev Gulmira Sultanbekova Kulparshan Kubenova Mira Baspayeva A first approach to identifying cardiotoxic effects of breast cancer chemotherapeutic treatment in Kazakhstan Ķazaķstannyṇ Klinikalyķ Medicinasy breast cancer cancer register chemotherapy cardiovascular events cardiotoxicity |
| title | A first approach to identifying cardiotoxic effects of breast cancer chemotherapeutic treatment in Kazakhstan |
| title_full | A first approach to identifying cardiotoxic effects of breast cancer chemotherapeutic treatment in Kazakhstan |
| title_fullStr | A first approach to identifying cardiotoxic effects of breast cancer chemotherapeutic treatment in Kazakhstan |
| title_full_unstemmed | A first approach to identifying cardiotoxic effects of breast cancer chemotherapeutic treatment in Kazakhstan |
| title_short | A first approach to identifying cardiotoxic effects of breast cancer chemotherapeutic treatment in Kazakhstan |
| title_sort | first approach to identifying cardiotoxic effects of breast cancer chemotherapeutic treatment in kazakhstan |
| topic | breast cancer cancer register chemotherapy cardiovascular events cardiotoxicity |
| url | https://www.clinmedkaz.org/download/a-first-approach-to-identifying-cardiotoxic-effects-of-breast-cancer-chemotherapeutic-treatment-in-11412.pdf |
| work_keys_str_mv | AT zhenisgultlegenova afirstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT saulebalmagambetova afirstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT bekbolatzholdin afirstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT gulnarakurmanalina afirstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT iliadatalipova afirstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT aripkoyshybaev afirstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT ainelurazova afirstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT dinaranurmanova afirstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT olzhasurazayev afirstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT gulmirasultanbekova afirstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT kulparshankubenova afirstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT mirabaspayeva afirstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT zhenisgultlegenova firstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT saulebalmagambetova firstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT bekbolatzholdin firstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT gulnarakurmanalina firstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT iliadatalipova firstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT aripkoyshybaev firstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT ainelurazova firstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT dinaranurmanova firstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT olzhasurazayev firstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT gulmirasultanbekova firstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT kulparshankubenova firstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan AT mirabaspayeva firstapproachtoidentifyingcardiotoxiceffectsofbreastcancerchemotherapeutictreatmentinkazakhstan |